2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Immunology, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3641 Hyperinflammation at diagnosis in aggressive non-Hodgkin lymphoma: Association with early mortality and patterns of hemophagocytic lymphohistiocytosis evaluation

Alexander D. Sanjurjo, B.S., Saagar Jain, BS2, Saara Kaviany, MD3, Hua-Jay Jeffery Cherng, MD4, Barbara Pro, MD5, Jennifer E. Amengual, MD6, Seda S. Tolu, MD7
1 Columbia University Vagelos College of Physicians & Surgeons, New York, New York, United States
2 Columbia University Vagelos College of Physicians & Surgeons, New York, New York, United States
3 Columbia University Irving Medical Center, New York, New York, United States
4 Columbia University Irving Medical Center, New York, New York, United States
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Columbia University Irving Medical Center, New York, New York, United States

Background: Aggressive non-Hodgkin lymphoma (NHL) can present with systemic hyperinflammation, including hemophagocytic lymphohistiocytosis (HLH). Lymphoma-associated HLH carries high mortality, making rapid recognition and treatment essential. The Optimized HLH Inflammatory index (Zoref-Lorenz 2022) combines ferritin >1000 ng/mL and soluble interleukin-2 receptor (sIL-2r) >3900 U/mL to identify high-risk patients, but sIL-2r testing is not widely accessible and has prolonged turnaround times. This study aimed to evaluate the association of baseline ferritin with 90-day mortality and overall survival (OS), and characterize patterns of HLH evaluation, in adults with newly diagnosed aggressive NHL.

Methods: We conducted a single-center retrospective study of adults diagnosed with aggressive NHL including diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) between 2010-2025 with ferritin values available within 3 months of diagnosis. Baseline ferritin was defined as the peak pre-treatment ferritin and patients were stratified into three groups: <500, 500-999, and ≥1000 ng/mL. Primary endpoints included OS and 90-day mortality. Survival difference was tested by log-rank and Cox proportional hazards; 90-day mortality by Fisher’s exact test and logistic regression. Clinical suspicion for HLH was assessed through clinician notes before the end of first-line treatment, with HLH-2004 criteria confirming diagnosis. Turnaround time for sIL-2r was calculated from collection to result date.

Results: Overall, 245 patients were included: 77% (n=189) DLBCL and 23% (n=56) PTCL. DLBCL cell-of-origin was 41% (n=78) GCB and 57% (n=107) non-GCB. The most common PTCL subtypes were: 36% (n=20) PTCL-NOS, 23% (n=13) AITL, and 14% (n=8) ALCL (n=3 ALK+, n=5 ALK-). Median age was 69 (IQR 57-78); most (72%; n=146) had stage III/IV disease and LDH levels above the upper limit of normal (ULN) (79%; n=189). Baseline ferritin was <500 in 50% (n=122), 500-999 in 23% (n=56), and ≥1000 in 27% (n=67). LDH > ULN differed across ferritin groups: 91% (n=61) for ferritin ≥1000, 78% (n=42) for ferritin 500-999, and 73% (n=86) for ferritin <500 (p=0.014). There were no differences in age, histology, or stage between the ferritin groups.

Median follow-up was 71 months (m) and median OS was 26.7m for the entire cohort (PTCL OS 10m, DLBCL OS 58.3m). OS differed by ferritin group (p<0.0001); median OS for patients with ferritin ≥1000 was 3.9m vs 76.7m for ferritin <500. Among patients with ferritin ≥1000, median OS was similar for those with DLBCL (3.6m) and PTCL (4.8m) (p=0.3). For patients with ferritin ≥1000, 90-day mortality was 42% compared with 14% for ferritin <500 (p<0.001). By univariable analysis, ferritin ≥1000 was associated with inferior OS (HR 2.54; CI 1.74, 3.69; p<0.001) and increased 90-day mortality (OR 4.27; CI 2.13, 8.79; p<0.001). By multivariable analysis adjusting for age, stage, histology, and LDH, ferritin ≥1000 remained associated with inferior OS (HR 1.94; CI 1.32, 2.85; p<0.001) and increased 90-day mortality (OR 3.66; CI 1.76, 7.81; p<0.001). Ferritin 500-999 was not associated with worse OS or increased 90-day mortality.

Of 67 patients with baseline ferritin ≥1000, 45% (n=30) had documented concern for HLH, with 67% of these patients (n=20) having had evaluation of sIL-2r. Median sIL-2r was 11,580 pg/mL (IQR 7,897-22,381) and median turnaround time was 3.4 days (IQR 2.4-4.6). Ultimately, 75% (n=15) of patients with sIL-2r results were confirmed to have HLH. Of the 13 patients that received HLH-directed therapy, 62% (n=8) did not have an sIL-2r result available at start of treatment, indicating turnaround time was too prolonged to inform initial treatment decisions.

Conclusion: In this retrospective analysis of patients with aggressive NHL, baseline ferritin ≥1000 independently identified a hyperinflammatory phenotype associated with inferior OS and increased 90-day mortality. Yet, more than half of patients with ferritin ≥1000 had no documented concern for HLH. When HLH was suspected, only two-thirds underwent sIL-2r testing, and prolonged turnaround times limited its utility in guiding initial treatment. These findings support routine assessment of baseline ferritin as an accessible first step to identify patients who may benefit from expedited HLH work-up and sIL-2r testing. Improving sIL-2r turnaround times is critical to better inform initial treatment decisions in this high-risk patient population.

Alexander D. Sanjurjo, B.S.: No relevant conflicts of interest to declare.